- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06411639
Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases
A Multicenter, Open-label, Single-arm, Multiple-dose Study to Characterize the Pharmacokinetics, Safety and Tolerability of Subcutaneous Ianalumab in Chinese Adult Participants With Autoimmune Diseases
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study consists of the following periods:
- Screening Period: up to 4 weeks
- Treatment Period (Week 0 - Week 12) : 12 weeks
Extended Treatment Period (after the completion of Week 12 - Week 52 (End of Treatment (EoT)) : 40 weeks
~ After completion of the 12-week treatment, participants will have the option to enter the Extended Treatment Period. If a participant does not enter the Extended Treatment Period, the EoT visit will be performed at the next planned visit following the completion of Week 12, followed by the Post-treatment Follow-up Period.
- Post-treatment Follow-up Period: at least 20 weeks and up to 2 years from the last dose of study treatment.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Novartis Pharmaceuticals
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
- Email: novartis.email@novartis.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Male and female patients 18 years to 70 years of age (inclusive)
- Body weight at least 35 kg and not more than 120 kg and must have a body mass index (BMI) within the range of 18 - 35 kg/m2. BMI = Body weight (kg) / [Height (m)]2 at screening
- Diagnosed with SjD and/or SLE as determined by the investigator
- Have active disease (SjD and/or SLE) that may benefit from B-cell depletion therapy, as determined by the investigator.
- Participants currently receiving protocol-allowed SoC should be on stable doses of SoC medications for 4 weeks prior to first dosing of study treatment
Key Exclusion Criteria:
- Use of prohibited therapies
- Active viral, bacterial or other infections requiring systemic treatment at the time of screening or baseline or history of recurrent clinically significant infection
- Receipt of live/attenuated vaccine within a 4-week period before first dosing
- Uncontrolled co-existing serious disease
- Pregnant or nursing (lactating) women
- Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, refusing or unable to use highly effective methods of contraception while on study treatment and for 6 months after stopping of study drug
Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ianalumab 300 mg
Participants will receive Ianalumab 300 mg subcutaneous (s.c.) monthly
|
ianalumab will be provided in a pre-filled Syringe (PFS) of 150 mg/1 mL for s.c.
administration.
Two injections of 1mL each will be administered monthly.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Curve (AUC) calculated to the end of a dosing interval (tau) at steady-state (AUCtau) of ianalumab after the 3rd dose
Time Frame: Week 8 to 12 (Day 57): Pre-dose, Post-dose (24 hours (hr) +/- 12hr, 72 hr +/- 24 hr, 168 hr +/- 72 hr, 336 hr +/- 72hr, 504 hr +/- 72hr)
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of ianalumab.
AUCtau of ianalumab will be summarized with descriptive statistics.
|
Week 8 to 12 (Day 57): Pre-dose, Post-dose (24 hours (hr) +/- 12hr, 72 hr +/- 24 hr, 168 hr +/- 72 hr, 336 hr +/- 72hr, 504 hr +/- 72hr)
|
Observed maximum blood concentration (Cmax)of ianalumab after the 3rd dose
Time Frame: Week 8 to 12 (Day 57): Pre-dose, Post-dose (24 hours (hr) +/- 12hr, 72 hr +/- 24 hr, 168 hr +/- 72 hr, 336 hr +/- 72hr, 504 hr +/- 72hr)
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of ianalumab.
Cmax of ianalumab will be summarized with descriptive statistics.
|
Week 8 to 12 (Day 57): Pre-dose, Post-dose (24 hours (hr) +/- 12hr, 72 hr +/- 24 hr, 168 hr +/- 72 hr, 336 hr +/- 72hr, 504 hr +/- 72hr)
|
Time of maximum observed drug concentration occurrence (Tmax) of ianalumab after the 3rd dose
Time Frame: Week 8 to 12 (Day 57): Pre-dose, Post-dose (24 hours (hr) +/- 12hr, 72 hr +/- 24 hr, 168 hr +/- 72 hr, 336 hr +/- 72hr, 504 hr +/- 72hr)
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of ianalumab.
Tmax of ianalumab will be summarized with descriptive statistics.
|
Week 8 to 12 (Day 57): Pre-dose, Post-dose (24 hours (hr) +/- 12hr, 72 hr +/- 24 hr, 168 hr +/- 72 hr, 336 hr +/- 72hr, 504 hr +/- 72hr)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ctrough of ianalumab at the end of dosing interval
Time Frame: Week 8 to 12 (Day 57): Pre-dose, Post-dose (24 hours (hr) +/- 12hr, 72 hr +/- 24 hr, 168 hr +/- 72 hr, 336 hr +/- 72hr, 504 hr +/- 72hr)
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of ianalumab.
Ctrough of ianalumab will be summarized with descriptive statistics.
|
Week 8 to 12 (Day 57): Pre-dose, Post-dose (24 hours (hr) +/- 12hr, 72 hr +/- 24 hr, 168 hr +/- 72 hr, 336 hr +/- 72hr, 504 hr +/- 72hr)
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Time Frame: From date of enrollment till 30 days after end of Treatment, assessed up to approximately 44 months
|
The distribution of adverse events will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.
|
From date of enrollment till 30 days after end of Treatment, assessed up to approximately 44 months
|
Anti-ianalumab antibodies (ADA)
Time Frame: Day 1 (Baseline), Week 8 to 11 Day 57 (Pre-dose), Week 12 Day 85, Week 24 Day 169, Week 36 Day 253, Week 52 Day 365, Week 68 Day 477 and Week 156 Day 1093
|
Immunogenicity (IG) blood samples will be collected for anti-drug antibodies characterization.
ADA of ianalumab will be summarized with descriptive statistics.
|
Day 1 (Baseline), Week 8 to 11 Day 57 (Pre-dose), Week 12 Day 85, Week 24 Day 169, Week 36 Day 253, Week 52 Day 365, Week 68 Day 477 and Week 156 Day 1093
|
Presence of anti-drug antibodies (ADA)
Time Frame: Day 1 (Baseline), Week 8 to 11 Day 57 (Pre-dose), Week 12 Day 85, Week 24 Day 169, Week 36 Day 253, Week 52 Day 365, Week 68 Day 477 and Week 156 Day 1093
|
Immunogenicity (IG) blood samples will be collected to assess the presence ADA of ianalumab.
|
Day 1 (Baseline), Week 8 to 11 Day 57 (Pre-dose), Week 12 Day 85, Week 24 Day 169, Week 36 Day 253, Week 52 Day 365, Week 68 Day 477 and Week 156 Day 1093
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Eye Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Stomatognathic Diseases
- Mouth Diseases
- Lacrimal Apparatus Diseases
- Arthritis, Rheumatoid
- Xerostomia
- Salivary Gland Diseases
- Dry Eye Syndromes
- Lupus Erythematosus, Systemic
- Autoimmune Diseases
- Sjogren's Syndrome
Other Study ID Numbers
- CVAY736A2104
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
Novartis PharmaceuticalsNot yet recruitingSystemic Lupus Erythematosus, SLE
-
Changhai HospitalRui Therapeutics Co., LtdRecruitingSystemic Lupus Erythematosus (SLE)China
-
Bioray LaboratoriesFirst Affiliated Hospital of Zhejiang UniversityRecruitingSystemic Lupus Erythematosus (SLE)China
-
Sohag UniversityNot yet recruitingSystemic Lupus Erythematosus (SLE)
-
BiogenEnrolling by invitationSystemic Lupus Erythematosus (SLE)Spain, Bulgaria, United States, China, Serbia, Mexico, Korea, Republic of, Chile, Argentina, Poland, Brazil, Japan, Romania, Colombia, Hungary, Czechia, United Kingdom, Taiwan, Philippines, Israel, France
-
AbbVieCompletedSystemic Lupus Erythematosus (SLE)United States, Argentina, Australia, Bulgaria, China, Colombia, Germany, Hungary, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Puerto Rico, Spain, Taiwan, United Kingdom
-
AmgenTerminatedActive Systemic Lupus ErythematosusKorea, Republic of, United States, Taiwan, Canada, Spain, Italy, Mexico, Japan, Turkey, Austria, Greece, Colombia, Switzerland, Poland, France, Bulgaria, Hong Kong, Russian Federation, Chile
Clinical Trials on ianalumab
-
Novartis PharmaceuticalsRecruitingLupus NephritisChina, United States, Spain, Germany, Korea, Republic of, Italy, Thailand, Hungary, Argentina, Brazil, Singapore, Taiwan, France, Vietnam, Malaysia, Lithuania, Canada, India, Colombia, Romania, United Kingdom, Czechia, Guatemala, Mexico, Eston... and more
-
Novartis PharmaceuticalsRecruitingSystemic Lupus ErythematosusUnited States, Germany, France, Taiwan, Italy, India, Argentina, Korea, Republic of, Mexico, Malaysia, Chile, Colombia, Romania, Australia, United Kingdom
-
Novartis PharmaceuticalsRecruiting
-
Novartis PharmaceuticalsRecruitingSystemic Lupus ErythematosusChina, Japan, United States, Spain, Thailand, Brazil, Singapore, Turkey, Israel, Hungary, Portugal, Slovakia, Guatemala, Poland, Czechia, Bulgaria, South Africa, Canada
-
Novartis PharmaceuticalsTerminatedPemphigus VulgarisTaiwan, United States, Austria, Bulgaria
-
Novartis PharmaceuticalsRecruitingSjogrens SyndromeJapan, United States, Spain, Austria, Belgium, Germany, Turkey, Hungary, Israel, Taiwan, Italy, France, Colombia, Argentina, Portugal, Australia, Slovakia, United Kingdom, Guatemala, Brazil, Czechia, Poland, Bulgaria, Canada, Lithuania, R...
-
Novartis PharmaceuticalsActive, not recruiting
-
Novartis PharmaceuticalsActive, not recruitingRheumatoid ArthritisGermany, Jordan
-
Novartis PharmaceuticalsRecruitingPrimary Immune Thrombocytopenia (ITP)Spain, Italy, France, Germany, China, Korea, Republic of, Czechia, Turkey, Malaysia, United States, Argentina, Australia, United Kingdom, Poland
-
Novartis PharmaceuticalsRecruitingWarm Autoimmune Hemolytic Anemia (wAIHA)China, Japan, Spain, Singapore, France, Germany, Taiwan, United States, Italy, India, Malaysia, Argentina, Hungary, Israel, Australia, Thailand, United Kingdom, Romania